GHP Investment Advisors Inc. Acquires 2,597 Shares of STERIS plc $STE

GHP Investment Advisors Inc. grew its holdings in STERIS plc (NYSE:STE) by 3.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 69,657 shares of the medical equipment provider’s stock after purchasing an additional 2,597 shares during the quarter. GHP Investment Advisors Inc. owned about 0.07% of STERIS worth $15,403,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Trust Co. of Vermont increased its position in STERIS by 30.2% in the 4th quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 38 shares in the last quarter. Bailard Inc. raised its stake in shares of STERIS by 3.5% in the fourth quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock worth $283,000 after acquiring an additional 38 shares during the last quarter. Magnolia Capital Advisors LLC lifted its position in shares of STERIS by 1.2% during the third quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock worth $888,000 after purchasing an additional 41 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 34.9% during the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 45 shares in the last quarter. Finally, Ascent Group LLC grew its stake in shares of STERIS by 4.9% during the fourth quarter. Ascent Group LLC now owns 1,009 shares of the medical equipment provider’s stock valued at $256,000 after purchasing an additional 47 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Stock Up 1.5%

Shares of NYSE:STE opened at $210.20 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The stock has a market cap of $20.49 billion, a price-to-earnings ratio of 26.51 and a beta of 0.93. The company has a 50 day moving average of $212.89 and a 200-day moving average of $233.42. STERIS plc has a one year low of $195.14 and a one year high of $269.44.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the company earned $2.74 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, sell-side analysts forecast that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s payout ratio is 31.78%.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and issued a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. KeyCorp decreased their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $278.00.

Insider Buying and Selling

In other news, VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the transaction, the vice president directly owned 35,259 shares in the company, valued at approximately $7,379,003.52. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 1,374 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the completion of the sale, the chief executive officer owned 63,647 shares in the company, valued at $13,493,164. This represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,328 shares of company stock valued at $1,554,051 over the last three months. Company insiders own 1.12% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.